Title : Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.

Pub. Date : 2007 Sep 21

PMID : 17662692






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Bortezomib ATP binding cassette subfamily B member 1 Homo sapiens
2 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Bortezomib ATP binding cassette subfamily B member 1 Homo sapiens
3 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Bortezomib ATP binding cassette subfamily B member 1 Homo sapiens
4 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Bortezomib ATP binding cassette subfamily B member 1 Homo sapiens
5 Our report provides evidence that MLN273 and, to a lesser degree, Bortezomib are both MDR-1-substrates, which might be relevant for drug-resistance in cancer. Bortezomib ATP binding cassette subfamily B member 1 Homo sapiens